Journal Information
Original article
Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab
Resultados preliminares en pacientes adultos con infección grave por SARS-CoV-2 tratados con tocilizumab
Adrián Sánchez-Montalváa,b,c,
, Júlia Sellarés-Nadala, Juan Espinosa-Pereiroa,b, Nuria Fernández-Hidalgoa,d, Santiago Pérez-Hoyose, Fernando Salvadora,b,c, Xavier Duràa, Marta Miaronsf, Andrés Antóng,d, Simeón Eremiev-Eremieva, Abiu Sempere-Gonzáleza, Arnau Monforte-Pallarésa, Pau Bosch-Nicolaua, Salvador Augustinh, Júlia Sampoli, Alfredo Guillén-del-Castilloj, Benito Almirantea,d
Corresponding author
a Infectious Diseases Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
b International Health Program of the Catalan Institut of Health (PROSICS), Barcelona, Spain
c Tropical Medicine Spanish Research Network (RICET), Madrid, Spain
d Infectous Diseases Spanish Research Network (REIPI), Madrid, Spain
e Statistic Unit, Vall d’Hebron Institute of Research, Barcelona, Spain
f Pharmacy Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
g Microbiology Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
h Hepatology Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
i Pneumology Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
j Internal Medicine Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
Ver más